Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S1470-2045(16)00144-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A phase IB study of binimetinib and palbociclib in molecularly selected advanced triple-negative breast cancer.
Cancer Res Commun
September 2025
Spanish National Cancer Research Centre, Madrid, Madrid, Spain.
Purpose: Advanced, pre-treated TNBC has a dismal prognosis and lacks effective options beyond standard cytotoxics. We previously showed, via phosphoproteomic screening, that CDK6 and ERK hyperactivation are linked to adverse outcomes and represent actionable targets. This prompted us to evaluate palbociclib and binimetinib in advanced TNBC after one or two prior therapies.
View Article and Find Full Text PDFMolecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1/2a NM umbrella trial.
Nat Med
September 2025
Neurology, University Clinic Heidelberg, Heidelberg University & German Cancer Consortium (DKTK) and CCU Neurooncology, German Cancer Research Center, Heidelberg, Germany.
Advances in molecular understanding and diagnostic precision of glioblastoma enable the identification of key genetic alterations in a timely manner and, in principle, allow treatments with targeted compounds based on molecular markers. Here we report the results of the phase 1/2 umbrella trial NCT Neuro Master Match (NM), which evaluated targeted treatments in 228 patients with newly diagnosed glioblastoma without O6-methylguanine DNA-methyltransferase promoter hypermethylation. Stratification for treatment was conducted by a trial-specific molecular tumor board across five subtrials, each evaluating a targeted therapy-alectinib, idasanutlin, palbociclib, vismodegib or temsirolimus-selected according to the best-matching molecular alteration.
View Article and Find Full Text PDFThe addition of CDK4/6 inhibitors to endocrine therapy has significantly improved outcomes in HR+/HER2- breast cancer. However, variable patient responses and acquired resistance remain a clinical challenge. We therefore defined the comprehensive molecular response to palbociclib, the most clinically used CDK4/6 inhibitor.
View Article and Find Full Text PDFMedication-Related Osteonecrosis of the Jaw induced by a CDK 4/6 inhibitor (Palbociclib) in a patient who was naïve to Antiresorptive Bone Therapy: A Case Report.
Oral Surg Oral Med Oral Pathol Oral Radiol
August 2025
Service d'Odontologie, CHU Clermont-Ferrand, Clermont-Ferrand, France; Université Clermont Auvergne, CHU Clermont-Ferrand, INSERM, Neuro-Dol, Clermont-Ferrand, France. Electronic address:
Medication-related osteonecrosis of the jaw (MRONJ) is a well-documented adverse effect initially linked to antiresorptive agents such as bisphosphonates. Over time, other drug classes have been associated with MRONJ: monoclonal antibodies targeting RANK ligand, monoclonal antibodies targeting VEGF, tyrosine kinase inhibitors, and mammalian target of rapamycin (mTOR) inhibitors. This article presents the case of an 83-year-old female patient referred to the maxillofacial surgery department due to a submental cutaneous fistula with purulent discharge and localized pain.
View Article and Find Full Text PDFNeoadjuvant palbociclib in women with operable, hormone receptor-positive breast cancer.
Endocr Relat Cancer
September 2025
Kyoto Breast Cancer Research Network, Japan.
The addition of a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor to endocrine therapy augments biological response in breast cancer. This phase III randomized, double-blind study evaluated the efficacy of adding palbociclib to neoadjuvant endocrine therapy (NET) for operable, hormone receptor-positive human epidermal growth factor receptor-2 (HER2)-negative breast cancer. Patients randomly received 16 weeks of endocrine therapy (letrozole for post-menopausal and tamoxifen plus ovarian function suppression for pre/peri-menopausal patients) plus palbociclib or placebo.
View Article and Find Full Text PDF